Zeta MMP-2 Antibody. Zeta’s monoclonal antibody recognizes MMP-2 (Matrix Metalloproteinase-2), an important sub-type of MMPs that has been found to be upregulated in different oncological conditions especially in breast cancer and chronic myeloid leukaemia (CML). Additionally, MMP-2 elevated expression is correlated with advanced CRC and aggressive tumor characteristics.
In cellular remodeling, MMPs are some of the most important enzymes are the proteases that mediate the tumor invasion. Matrix metalloproteinase (MMP) is an ensemble of 26 human zinc dependent metalloproteinases out of which 24 are available in humans. MMPs are proteolytic enzymes capable of degrading connective tissue components. They have a common mode of activation, a conserved amino acid sequence in the putative metal binding-active site region and are inhibited by specific tissue inhibitors of metalloproteinases (TIMPs). MMPa and TIMPs play a significant role in regulating angiogenesis. MMP-2 is synthesized as a 631 amino acid proenzyme which is activated by cleavage of the first 80 amino acids. The MMP-2 antibody reacts with both latent and active MMP-2.